Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches - Takeaways - MDSpire

Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches

  • By

  • Takashi Takeshita

  • Vittorio Gebbia

  • San-Gang Wu

  • June 11, 2026

  • 0 min

Share

  • 1

    Low ER/PgR expression breast cancer occupies a complex therapeutic space between luminal and triple-negative breast cancer.

  • 2

    Current ASCO/CAP guidelines inadequately address the heterogeneity of ER/PgR low-expression tumors, complicating treatment decisions.

  • 3

    Approximately 75–80% of ER-low tumors are non-luminal and basal-like, with outcomes resembling triple-negative breast cancer.

  • 4

    Emerging therapies, including CDK4/6 inhibitors and immunotherapy, require further investigation in ER/PgR low-expression breast cancer.

  • 5

    A biologically informed approach integrating molecular subtyping and immune profiling is essential for managing ER/PgR low-expression breast cancer.

Original Source(s)

Editorial: Challenges and strategies in the management of ER/PgR Low-expression breast cancer: exploring fundamentals, clinical insights, and treatment approaches

  • by Takashi Takeshita, Vittorio Gebbia, San-Gang Wu

  • June 11, 2026

Related Content

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

Bulk and single-cell RNA sequencing data identified HMGB3 of chromatin regulators as a breast cancer biomarker associated with the cell cycle